NCT03246399View on ClinicalTrials.gov

A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 26, 2017

Primary Completion Date

November 14, 2018

Study Completion Date

December 4, 2018

Conditions
Degenerative Disc Disease
Interventions
DRUG

SM04690

suspension formulation of SM04690, delivered via intradiscal injection (single injection)

Trial Locations (4)

23235

Research Site, Richmond

29406

Research Site, Charleston

75701

Research Site, Tyler

92103

Research Site, San Diego

Sponsors
All Listed Sponsors
lead

Biosplice Therapeutics, Inc.

INDUSTRY

NCT03246399 - A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease | Biotech Hunter | Biotech Hunter